Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models

Webinar: Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models

Larger companies often limit their strategic pharmacovigilance activities outsourcing only to highly manual and repetitive tasks, while the smaller ones may want to outsource their entire pharmacovigilance system. But is there anything in between?

  • How can larger companies benefit from outsourcing strategic pharmacovigilance activities while maintaining full control and compliance?
  • How can small/medium-sized companies get access to a serious pharmacovigilance database that grows with them without having to break the bank?
  • What are the advantages of scalable and tailor-made outsourcing models?
  • How can the pharmaceutical companies obtain benefits from the scalability and standardization required to ensure central oversight while also retaining local effectiveness?

 

You will learn about strategic pharmacovigilance activities outsourcing through scalable and tailor-made outsourcing models and how it can be done in a controlled way:

 

1. Full pharmacovigilance outsourcing

  • What does it mean?
  • How will you remain in control?

2. Outsourcing a pharmacovigilance database

  • How to select a proper database?
  • How to get access to it without buying it yourself?
  • What control levels can you opt for?

3. Outsourcing specific strategic pharmacovigilance activities

  • How to remain in control?

Optimizing your pharmacovigilance activities?

Make use of our experts’ invaluable know-how in managing pharmacovigilance activities while remaining in control.

Who should attend?

  • Global QPPVs / Deputies
  • QPPV Office managers
  • Heads of Pharmacovigilance
  • Heads of Pharmacovigilance Technologies
  • Drug Safety Managers
  • Drug Safety Leaders involved in Risk Management, Aggregate Safety reports, Oversight and Standards

Duration: 50 min.

Speakers:

  • Head of Global Pharmacovigilance, Martijn van de Leur;
  • International QPPV, Olga Asimaki;
  • QPO Manager and Head of Pharmacovigilance Technologies, Gediminas Zvicevičius.
Martijn van de Leur, MSc

Martijn van de Leur, MSc

Head of Global Pharmacovigilance

Other content that might interest you:

Effective IMPD Writing. The Quality Part

Effective IMPD Writing. The Quality Part

Webinar: Effective IMPD Writing. The Quality Part Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is...

read more
Medical Device Registration in Russia. The Essentials

Medical Device Registration in Russia. The Essentials

Webinar: Successful Medical Device Registration in Russia. The Essentials The current national system for Medical Device registration in Russia was created from scratch and entered into force in 2013. Most experts agree that this system is complex and puzzling – some...

read more
Setting Up A Pharmacovigilance System

Setting Up A Pharmacovigilance System

Setting Up a Pharmacovigilance System from Scratch In the EU/EEA, US, and other major pharmaceutical markets, you need a sound plan for post-market surveillance for your medicinal product's Market Authorization Application (MAA). A robust pharmacovigilance (PV) system...

read more
Advantages of QPPV Outsourcing in the EU/EEA

Advantages of QPPV Outsourcing in the EU/EEA

Advantages of QPPV Outsourcing in the EU/EEA Pharmaceutical companies with a primary base outside the EU, companies without in-house PV capabilities or companies with business decisions to refocus their workload on core strategic competencies often look to externalize...

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information